|
| miRNAs | Tumor type | Effect | References |
|
| miR-195-3p | Renal cell carcinoma | miR-195-3p is upregulated in renal cell tissues and cell lines (786-O, 769P, and ACHN). Overexpression of miR-195-3p can enhance renal cell carcinoma proliferation, migration, and invasion while inhibiting cell apoptosis. | [24] |
| Cervical cancer | miR-195-3p is downregulated and BCDIN3D is upregulated. miR-195-3p suppresses cervical cancer cell proliferation by targeting BCDIN3D. | [25] |
| Oral squamous cell carcinoma | Downregulation of miR-195-3p increases VEGF-C expression decreases lymphangiogenesis, and therefore inhibits lymph node metastasis, reducing the risk of recurrence and metastasis in patients. | [26] |
|
| miR-5571-5p | N/A | miR-5571-5p has the potential to be a diagnostic biomarker for dilated cardiomyopathy and is related to NYHA classification, but there is no research on the occurrence and progression of tumors. | [27] |
|
| miR-584-3p | Colon cancer | The expression of miR-584-3p is negatively correlated with LOC101927746 or SSRP1 in colon cancer tissues. LOC101927746 has the potential to be utilized as a competitive endogenous RNA to inhibit miR-584-3p and activate its target gene SSRP1. The high expression of LOC101927746 indicates the poor prognosis of colon cancer patients. | [28] |
| Glioma | miR-584-3p is linked to the vasculogenic mimicry (VM) of glioma cells. It is possible to inhibit the VM of malignant glioma as an effective tumor suppressor gene, which can be used as a prognostic biomarker of glioma and has potential significance for gene therapy of glioma. | [29] |
| Stomach cancer | miRNA-584-3p inhibits the progression of gastric cancer by inhibiting MMP-14 expression, which is promoted by Yin Yang 1 (YY1) and is an independent prognostic factor for a good prognosis of gastric cancer. | [30] |
| Renal cell carcinoma | miR-875-3p is potentially a possible biomarker for the survival of patients with renal cell carcinoma, which is linked to patient prognosis. | [31] |
| Malignant melanoma | miR-584-3p significantly inhibits the mobility and growth of metformin-induced malignant melanoma cells by silencing the target genes EFEMP1 and SCAMP3. | [32] |
|
| miR-494-3p | Endometrial cancer | The expression level of miR-494-3p was significantly upregulated in EC. miR-494-3p can promote the progression of endometrial cancer by regulating the PTEN/PI3K/AKT pathway. | [33] |
| Glioma | MiR-494-3p expression is considerably upregulated in neurocytoma and is inversely associated with WT1-AS expression. Co-transfection of WT1-AS and miR-494-3p reduces the activation of phosphorylated AKT (p-AKT), thereby regulating the protective immune response of malignant tumors. | [34] |
| Retinoblastoma | miR-494 has the potential to act as a tumor promoter and regulate tumor progression. | [35] |
| Hepatocellular carcinoma | The expression level of miR-494-3p was significantly upregulated in liver cancer tissues. It has the potential to promote the progression of hepatocellular carcinoma by regulating the PTEN/PI3K/AKT pathway. | [36] |
| Synovial sarcoma | The expression of miR-494-3p is downregulated in synovial sarcoma tissues, which increases the expression of its potential target CXCR4, thereby promoting its metastasis. | [37] |
| Oral Squamous Cell Carcinoma | miR-494-3p acts as a tumor suppressor miRNA in OSCC. miR-494-3p may enhance the radio-sensitivity of SAS OSCC cells and induce cell senescence. | [38] |
| Osteosarcoma | The expression of miR-494-3p is downregulated in osteosarcoma tissue, and the malignant biological behavior of OS cells is promoted through the circ_0081001/miR-494-3p/BACH1 axis. | [39] |
| Prostate cancer | The downregulation of miR-494-3p expression in prostate cancer may play a key role in prostate cancer through posttranscriptional regulation of CXCR4 mRNA. | [40] |
| Non-small cell lung cancer | miR-494-3p is significantly upregulated in NSCLC cell lines. lncRNA WT1-AS mediates the PTEN/PI3K/AKT pathway in NSCLC through negative regulation of miR-494-3p, which inhibits cell proliferation, migration, and invasion but accelerates cell apoptosis. | [41] |
|
| miR-4664-3p | Small cell carcinoma of the esophagus | miR-4664-3p was shown to be associated with postoperative recurrence in patients with esophageal small cell carcinoma. | [42] |
|
| miR-1293 | Pancreatic cancer | miR-1293 can be used as a prognostic marker for pancreatic cancer and may be involved in various cancer-related pathways, including PI3K-Akt, TGF-β, and pluripotent stem cell signaling pathways. | [43] |
| Papillary renal cell carcinoma | Using the Cox ratio risk regression model, miR-1293 can be used as a prognostic marker for papillary renal cell carcinoma, suggesting that it may act as an oncogene in the development of tumors. | [44] |
| Lung adenocarcinoma | miR-1293 is significantly related to the survival rate of LUAD patients, can be used as a new biomarker to predict the prognosis of LUAD, and is highly enriched in systemic lupus erythematosus pathways. | [45] |
|
